Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : Goldman Sachs Adjusts Price Target for Johnson & Johnson to $201 From $181, Maintains Buy Rating

01/27/2021 | 09:22am EDT


ę MT Newswires 2021
All news about JOHNSON & JOHNSON
04:19pJOHNSON & JOHNSON : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
01:01pEMERGENT BIOSOLUTIONS : resumes COVID-19 vaccine production
AQ
12:06pJOHNSON & JOHNSON : SA to Soon Administer Over 300,000 Covid-19 Vaccines a Day
AQ
11:16aJOHNSON & JOHNSON : Women Cancer Victims Opposed to Johnson & Johnson's 'Texas T..
PR
11:06aJOHNSON & JOHNSON : and Vaccine Gets Approval
AQ
10:04aJOHNSON & JOHNSON : Statement on U.S. FDA Approval of Shelf Life Extension for C..
AQ
09:33aBIOHIT OYJ : Appoints New CEO
MT
05:44aLABORATORIO REIG JOFRE S A : Reig Jofre Delays Manufacturing of Johnson & Johnso..
MT
02:01aBIOHIT OYJ : Päivi Siltala new CEO of Biohit Oyj
AQ
12:08aJOHNSON & JOHNSON : What is a COVID-19 vaccine 'breakthrough' case?
AQ
More news
Financials (USD)
Sales 2021 94 452 M - -
Net income 2021 22 808 M - -
Net Debt 2021 853 M - -
P/E ratio 2021 20,2x
Yield 2021 2,41%
Capitalization 453 B 453 B -
EV / Sales 2021 4,81x
EV / Sales 2022 4,59x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 172,18 $
Average target price 184,35 $
Spread / Average Target 7,07%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON9.40%453 418
ROCHE HOLDING AG12.49%332 374
PFIZER, INC.18.04%243 220
ELI LILLY AND COMPANY46.00%224 084
NOVARTIS AG0.39%223 750
ABBVIE INC.10.64%209 386